BIONTECH News & Analysis

We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.

Three new vaccines for coronavirus look poised for emergency use authorisation in the US this autumn. What does that mean for investors?

A long road lies ahead as the trial continues, but we are maintaining our fair value estimates for the two healthcare firms, says Morningstar’s...